{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:24:33Z","timestamp":1767828273582,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"crossref","award":["AGL2016-79813-C2-1R"],"award-info":[{"award-number":["AGL2016-79813-C2-1R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"crossref","award":["SAF2017-83575-R"],"award-info":[{"award-number":["SAF2017-83575-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FEDER, UE","award":["LE020P17"],"award-info":[{"award-number":["LE020P17"]}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.drudis.2019.03.007","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:27:01Z","timestamp":1552393621000},"page":"1209-1216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Walking a tightrope: drug discovery in visceral leishmaniasis"],"prefix":"10.1016","volume":"24","author":[{"given":"Rafael","family":"Bala\u00f1a-Fouce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Yolanda","family":"P\u00e9rez Pertejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Dom\u00ednguez-Asenjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camino","family":"Guti\u00e9rrez-Corbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa M.","family":"Reguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.03.007_bib0005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.03.007_bib0010","first-page":"1","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"20","author":"Uliana","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.drudis.2019.03.007_bib0015","series-title":"Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region","author":"WHO","year":"2005"},{"key":"10.1016\/j.drudis.2019.03.007_bib0020","series-title":"Memorandum of understanding among Bangladesh, Bhutan, India, Nepal and Thailand on the elimination of kala-azar from the South-East Asia region","author":"World Health Organization South-East Asia","year":"2014"},{"key":"10.1016\/j.drudis.2019.03.007_bib0025","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/S1473-3099(16)30140-2","article-title":"Elimination of visceral leishmaniasis on the Indian subcontinent","volume":"16","author":"Singh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0030","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1093\/cid\/ciy007","article-title":"Policy recommendations from transmission modeling for the elimination of visceral leishmaniasis in the Indian subcontinent","volume":"66","author":"Le Rutte","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0035","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.03.007_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.03.007_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4269\/ajtmh.17-0142","article-title":"Visceral leishmaniasis and HIV co-infection in Northwest Ethiopia: antiretroviral treatment and burden of disease among patients enrolled in HIV care","volume":"98","author":"Van Griensven","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.drudis.2019.03.007_bib0050","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"Musa","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0055","doi-asserted-by":"crossref","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of Ambisome for treatment of visceral leishmaniasis in Eastern Africa: a randomised trial","volume":"8","author":"Khalil","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0060","unstructured":"Pan American Health Organization. Leishmaniasis: Epidemiological Report of the Americas. February, 2018."},{"key":"10.1016\/j.drudis.2019.03.007_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005706","article-title":"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial","volume":"11","author":"Romero","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.drudis.2019.03.007_bib0080","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","article-title":"Repurposing strategies for tropical disease drug discovery","volume":"26","author":"Klug","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2019.03.007_bib0085","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2533\/chimia.2017.661","article-title":"Chemical space: big data challenge for molecular diversity","volume":"71","author":"Awale","year":"2017","journal-title":"Chimia"},{"key":"10.1016\/j.drudis.2019.03.007_bib0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13321-017-0225-z","article-title":"An algorithm to identify functional groups in organic molecules","volume":"9","author":"Ertl","year":"2017","journal-title":"J. Cheminf."},{"key":"10.1016\/j.drudis.2019.03.007_bib0095","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1039\/C7NP00028F","article-title":"Expansion of chemical space for natural products by uncommon P450 reactions","volume":"34","author":"Zhang","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.drudis.2019.03.007_bib0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrd.2018.53","article-title":"Chemical probes and drug leads from advances in synthetic planning and methodology","volume":"17","author":"Gerry","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2016.12.029","article-title":"Ligand and target discovery by fragment-based screening in human cells","volume":"168","author":"Parker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2019.03.007_bib0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acsinfecdis.7b00244","article-title":"Genetically validated drug targets in Leishmania: current knowledge and future prospects","volume":"4","author":"Jones","year":"2018","journal-title":"ACS. Infect. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.drudis.2019.03.007_bib0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0125","doi-asserted-by":"crossref","first-page":"e1671","DOI":"10.1371\/journal.pntd.0001671","article-title":"An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages","volume":"6","author":"Siqueira-Neto","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0130","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0135","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"De Rycker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2019.03.007_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006157","article-title":"Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening","volume":"11","author":"Ortiz","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0150","series-title":"Methods and Principles in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/9783527677047.ch12","article-title":"A medicinal chemistry perspective on the hit-to-lead phase in the current era of drug discovery","author":"Brown","year":"2016"},{"key":"10.1016\/j.drudis.2019.03.007_bib0155","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1038\/s41598-018-30040-5","article-title":"Importance of secondary screening with clinical isolates for anti-leishmania drug discovery","volume":"8","author":"Hefnawy","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.03.007_bib0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpba.2017.07.023","article-title":"Cell cultures in drug discovery and development: the need of reliable in vitro\u2013in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment","volume":"147","author":"Jaroch","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2019.03.007_bib0165","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1021\/acs.jmedchem.7b00487","article-title":"In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development","volume":"60","author":"Lombardo","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.007_bib0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1017\/S0031182017001664","article-title":"Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD","volume":"145","author":"Croft","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.drudis.2019.03.007_bib0175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/17460441.2016.1165203","article-title":"The development of high-content screening (HCS) technology and its importance to drug discovery","volume":"11","author":"Fraietta","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0180","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.03.007_bib0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2741\/e820","article-title":"Development of a semi-automated image-based high-throughput drug screening system","volume":"10","author":"Eren","year":"2018","journal-title":"Front. Biosci."},{"key":"10.1016\/j.drudis.2019.03.007_bib0190","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drudis.2019.03.007_bib0195","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-b[1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.drudis.2019.03.007_bib0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpddr.2018.01.006","article-title":"In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series","volume":"8","author":"Van den Kerkhof","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.drudis.2019.03.007_bib0205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.03.007_bib0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"8","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2019.03.007_bib0215","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.007_bib0220","article-title":"Identification of GSK3186899\/DDD853651 as a preclinical development candidate for the treatment of visceral leishmaniasis","author":"Thomas","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.03.007_bib0225","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1371\/journal.pntd.0000252","article-title":"Macrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi","volume":"2","author":"Ettinger","year":"2008","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004992","article-title":"Meta-transcriptome profiling of the human-Leishmania braziliensis cutaneous lesion","volume":"10","author":"Christensen","year":"2016","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","article-title":"Screening out irrelevant cell-based models of disease","volume":"15","author":"Horvath","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2019.03.007_bib0240","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1371\/journal.pntd.0000962","article-title":"Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system","volume":"5","author":"Osorio","year":"2011","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003666","article-title":"Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis","volume":"9","author":"Calvo-\u00c1lvarez","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0250","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"Gautam","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0255","first-page":"27","article-title":"Visceral leishmaniasis: experimental models for drug discovery","volume":"133","author":"Gupta","year":"2011","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.drudis.2019.03.007_bib0260","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1902s108","article-title":"Animal models for the analysis of immune responses to leishmaniasis","author":"Sacks","year":"2015","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.drudis.2019.03.007_bib0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00281-015-0548-7","article-title":"Lessons from other diseases: granulomatous inflammation in leishmaniasis","volume":"38","author":"Kaye","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.drudis.2019.03.007_bib0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13071-016-1413-9","article-title":"Study of Leishmania pathogenesis in mice: experimental considerations","volume":"9","author":"Loeuillet","year":"2016","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.drudis.2019.03.007_bib0275","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1574-6976.2010.00252.x","article-title":"Noninvasive biophotonic imaging for studies of infectious disease","volume":"35","author":"Andreu","year":"2011","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.drudis.2019.03.007_bib0280","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1371\/journal.pntd.0000034","article-title":"Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL\/6 Model","volume":"1","author":"Lecoeur","year":"2007","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0285","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00270-08","article-title":"Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery","volume":"15","author":"Mehta","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.drudis.2019.03.007_bib0290","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.exppara.2010.12.006","article-title":"Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies","volume":"127","author":"Bolhassani","year":"2011","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.drudis.2019.03.007_bib0295","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1371\/journal.pntd.0001927","article-title":"Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis","volume":"6","author":"Calvo-\u00c1lvarez","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.mimet.2016.08.003","article-title":"In vivo near-infrared fluorescence imaging of Leishmania amazonensis expressing infrared fluorescence protein (iRFP) for real-time monitoring of cutaneous leishmaniasis in mice","volume":"130","author":"Oliveira","year":"2016","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.drudis.2019.03.007_bib0305","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1371\/journal.pntd.0001323","article-title":"Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro","volume":"5","author":"Michel","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003556","article-title":"Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging","volume":"9","author":"Reim\u00e3o","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005924","article-title":"New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence","volume":"11","author":"Melo","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.drudis.2019.03.007_bib0320","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.meegid.2018.01.011","article-title":"A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and Leishmania parasites","volume":"63","author":"Calvo-Alvarez","year":"2018","journal-title":"Infect. Genet. Evol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:38:00Z","timestamp":1761223080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618304756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1359644618304756"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.007","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Walking a tightrope: drug discovery in visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}